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Abstract
Background: The emergence of tuberculosis resistant to multiple first- and second-line antibiotics poses challenges to a
global control strategy that relies on standard drug treatment regimens. Highly drug-resistant strains of Mycobacterium
tuberculosis have been implicated in outbreaks and have been found throughout the world; a comprehensive
understanding the magnitude of this threat requires an accurate assessment of the worldwide burden of resistance.
Unfortunately, in many settings where resistance is emerging, laboratory capacity is limited and estimates of the burden of
resistance are obtained by performing drug sensitivity testing on a sample of incident cases rather than through the use of
routine surveillance.
Methodology/Principal Findings: Using an individual-based dynamic tuberculosis model to simulate surveillance strategies
for drug resistance, we found that current surveys may underestimate the total burden of resistant tuberculosis because
cases of acquired resistance are undercounted and resistance among prevalent cases is not assessed. We explored how this
bias is affected by the maturity of the epidemic and by the introduction of interventions that target the emergence and
spread of resistant tuberculosis.
Conclusions: Estimates of drug resistant tuberculosis based on samples of incident cases should be viewed as a lower
bound of the total burden of resistance.
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Introduction
Extensively drug-resistant tuberculosis (XDR TB) has been
documented in forty-seven countries on six continents [1]; XDR
TB is characterized by resistance to the two most important anti-
TB drugs (isoniazid and rifampin) plus additional resistance to at
least one fluoroquinolone and one injectable antibiotic [2]. While
the most TB cases worldwide can be effectively treated with
standard drug regimens, the unchecked emergence of resistance
may compromise the effectiveness of global disease control
strategies [3]. In order to assess the need for and design control
strategies that can address the threat of emerging resistance, public
health practitioners need an accurate assessment of the burden of
drug-resistant tuberculosis.
Unfortunately, in many high-burden settings, the paucity of
laboratories equipped to perform routine culture and drug-
susceptibility testing hampers efforts to document the extent of
the problem. In these resource-constrained settings, estimates of
resistance are determined through periodic surveys of incident (i.e.
presenting) TB cases rather than through ongoing surveillance.
The existing guidelines for the design of these drug-resistance
surveys emphasize that valid inference requires that individuals
included in the sample must be randomly selected from the total
population of incident tuberculosis cases in the region under
evaluation. Additionally, these guidelines suggest that individuals
with first-time tuberculosis should be analyzed separately from
those with recurrent disease, since those with recurrent disease are
more likely to harbor resistant strains [4].
While this type of survey allows the estimation of resistance
among newly-occurring or recurring cases of TB, we suggest that
incidence-based samples may underestimate the total burden of
drug-resistant tuberculosis in a community. First, since these
surveys are conducted among individuals with a new or recurrent
diagnosis of tuberculosis, patients who acquire drug resistance
while enrolled in a treatment program may not be re-registered as
recurrent cases, and thus would be less likely to be included in the
study sample. Second, we propose that the total burden of
resistance should also reflect the extent of resistance among
prevalent (i.e. extant) TB in a community, since these individuals
are the potential source cases for transmitted resistance, and
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antibiotics. Individuals with drug-resistant disease are likely to
experience longer durations of illness, since they will respond less
favorably to standard drug regimens; therefore, the proportion of
prevalent cases that is resistant is likely to exceed the proportion of
incident cases that is resistant.
In this paper we describe a simple dynamic model of TB
transmission designed to simulate the performance of incidence-
based sampling methods. We use this model to examine the
validity of sample-based estimates of the total burden of drug
resistance and explore how the magnitude of bias in these sample-
based estimates is affected by the maturity of the drug-resistant
tuberculosis epidemic and the implementation of different types of
public health interventions.
Methods
Tuberculosis model
Generation of transmission networks. We simulate the
natural history and transmission of drug-sensitive and drug-
resistant strains of tuberculosis over a simple idealized contact
network in which transmission of disease is more likely to occur
between individuals who are in close socio-spatial proximity.
These networks are not intended to capture the contact structure
of any particular population, rather they aim to represent the
concept that individuals are more likely to contact others who
reside and circulate within their social context than other
individuals randomly selected from the population. The
generation of these networks is described fully in a previous
manuscript [5]; briefly, following the method of Read & Keeling
[6], we generate a population in which each individual is placed at
random on a square patch at a constant average density. We
depict contacts between these individuals as edges connecting
vertices, with the presence of an edge signifying sufficient contact
for transmission of disease. The probability of an edge between
two individuals decreases as the distance between them increases,
such that infection is transmitted preferentially to individuals in the
proximity of an infectious case. Thus, individuals located nearest
each other on the network can be thought of as family members,
while those slightly further away may be neighbors, friends, or
other social contacts. We specify how ‘‘clustered’’ the network is by
setting a single parameter D (lower D = higher cliquishness) and
assign an average number of contacts (i.e. degree) by specifying a
second parameter n. We use the relationship
p~
n
2pD2 e
{d2=2D2
such that for any two vertices separated by a distance d, the
probability of an edge linking them is equal to p.
Modeling the natural history and transmission of TB on
the network. We model the natural history of tuberculosis using
a modified susceptible-latent-infectious-recovered (SEIR) model
where each individual is born susceptible (S) and has a probability
(w) of being infected during each month of contact with one or
more infectious individuals. Upon infection, an individual
transitions to a state of latent infection (E) from which he or she
may progress to active tuberculosis disease (I) (Fig. 1A). The
probability of progression from latent infection to disease is
dependent on the duration of infection; here, the risk of
progression is greatest within five years of an infection event,
and is much reduced after this period has elapsed [7,8]. A latently
infected individual may also be re-infected by a second circulating
strain of M. tuberculosis, though latently infected individuals retain
partial immunity to re-infection (Fig. 1B). Individuals recovering
from tuberculosis, either through treatment or self-recovery,
transition back to a state of latency from which they have only a
small probability of progression.
We include two strain phenotypes in this model, one which we
designate ‘‘drug sensitive’’ (DS) and one which we designate ‘‘drug
resistant’’ (DR). These broad categorizations, and the associated
strain-specific parameter values, are intended to reflect the fact
that some strains of tuberculosis respond well to standard multiple-
drug chemotherapeutic regimens (e.g. strains without any
resistance or with resistance to only single drugs in the regimen),
while other strains that are resistant to more than one drug
(especially those with resistance to the two most powerful drugs,
isoniazid and rifampin) respond relatively poorly to standard
treatment regimens [9]. Mycobacterial resistance to anti-tubercu-
losis drugs initially emerges within treated hosts by the selection of
rare, sporadically-occurring mutants under conditions of inade-
quate chemotherapy (acquired drug resistance; Fig. 2, arrow b).
Once resistant strains have emerged, these strains can be
transmitted to others (transmitted, or primary, resistance; Fig. 2,
arrow c). We model the emergence of DR assuming that resistance
first occurs in a fraction of individuals who are on treatment for
active disease, and may then be transmitted to their contacts. For
simplicity, we model the acquisition of the DR phenotype as a
single-step process, while in reality resistance to multiple
antibiotics is caused by sequentially-occurring mutations
[10,11,12]. Since individuals with DR disease are less responsive
to standard therapeutic regimens, they will, on average, experience
a longer duration of infectiousness, and therefore also a higher
case fatality.
We assume that most resistance-conferring mutations disrupt
gene function and thus exact a fitness cost which may reduce the
pathogen’s ability to be transmitted and/or to cause disease.
Previous models have demonstrated that the relative fitness of DR
strains compared with DS strains is a key determinant of the
trajectory of DR tuberculosis epidemics [13,14,15], and the mean
relative fitness of DR strains may increase over time as more fit
DR strains are preferentially transmitted [16]. Studies suggest that
while laboratory-derived drug-resistant bacterial isolates usually
have substantial fitness deficits, resistant strains collected from
clinical specimens may not be similarly impaired [17–24]. For the
baseline simulations we present, we assume that the DR strain has
a fixed moderate fitness cost which reduces both the probability of
transmission and the probability of progression after infection by
20% each; in further analyses, we discuss how an increasing mean
relative fitness among DR strains over the course of a drug
resistant TB epidemic would affect our results.
We calculate each individual’s per month probability of
infection with either the DS or the DR strain (wDS, wDR) by first
considering the probability of not being infected (,wDS, ,wDR).
Given that tDS and tDR are the infectiousness per month of drug-
sensitive and drug-resistant infectious contacts, respectively, and
that kDS and kDR are the number of each type of contact, then
,wDS=(12tDS)
kDS and ,wDR=(12tDR)
kDR. Thus, the total
probability of being infected with either strain is equal to one
minus the product of these two, that is, w=12[(,wDS)(,wDR)].
Since we allow that only one infection event can occur per time
step, the final probabilities of infection are the products of the total
probability and the proportion of neighbors infectious with each
strain:
wDS~ kDS= kDSzkDR ðÞ ½  w and wDR~ kDR= kDSzkDR ðÞ ½  w:
For individuals in the latently infected state, who remain only
TB Drug Resistance Surveys
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reduced by the immunity factor.
Recent investigations suggest that concurrent infection with
multiple strains is possible and may not be unusual in high-disease-
burden settings, where the force of infection is large [25–31]. In
this model, we include a state of mixed latency to reflect the fact
that some individuals may harbor infection with both DR and DS
strains; therefore, each individual in the model is in one of six
states: susceptible (S), drug-sensitive latent infection (EDS), drug-
resistant latent infection (EDS), mixed latent infection (EM), active
drug-sensitive tuberculosis (IDS), or active drug-resistant tubercu-
losis (IDR). Parameter values (Table S1, Figure S1) and additional
modeling details (Supplement S1, Figure S2), are provided in the
supplementary material.
Simulating drug-resistance surveys
To illustrate the performance of drug-resistance surveys
conducted during tuberculosis epidemics, we compare the
estimated burden of drug resistance obtained from incidence-
based surveys to the actual proportion of drug resistance among (i)
incident and (ii) prevalent cases of disease as drug resistant TB
emerges in the population. We use the emerging epidemic of drug-
resistant TB in the Russian Federation between 1990 and 2003 as
a guideline to simulate growing epidemic of multidrug resistant TB
(MDR TB–resistance to at least isoniazid and rifampin), choosing
transmission parameters accordingly and taking other parameters
from the literature (Supplement S1, Table S1). The key features of
this epidemic are that there is a rising burden of TB as well as drug
resistant TB and that it is not heavily influenced by an HIV co-
epidemic. We note that our model should not be viewed as a
model for the tuberculosis epidemic in a specific geographic
location, rather we use it as a general example of an emerging
drug resistant TB epidemic in the absence of HIV. During this
time period, the estimated total TB incidence rose from 48 to 112
cases per 100,000 per year [32]. Trends in the proportion of MDR
among incident cases were estimated using a weighted average of
Figure 2. Mechanisms of resistance. Incidence of drug-sensitive TB (DS TB) contributes to the pool of prevalent DS TB (arrow a). Incidence of
drug-resistant TB (DR TB) occurs either through acquired drug resistance (arrow b) or through transmitted/primary resistance (arrow c).
doi:10.1371/journal.pone.0002363.g002
Figure 1. A) Natural history of TB infection. Individuals are born susceptible to infection by either DS or DR TB. Latently infected individuals can be re-
infected by any circulating strain; if re-infected by the other strain, they transition to a state of mixed latency. The risk of progression to TB disease
from latently infected states depends on the time since the most recent infection event. DR TB first appears through the acquired route and can then
be transmitted. Individuals in the infectious states suffer a higher disease-specific risk of death, and those with DR TB are less likely to be effectively
treated by antibiotics. B) The probability of progression to disease is dependent on the time elapsed since infection. Individuals who are recently
infected or re-infected (within 5 years of such events) experience an increased risk of progression to active TB disease compared with individuals who
were infected or re-infected at more distant times.
doi:10.1371/journal.pone.0002363.g001
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in 1998, 2000, 2001, and 2002. Over this span, the proportion of
incident cases that were highly resistant rose from approximately 9
to 19% [33]. We then extend the simulations for an additional 10
years to permit us to explore changes in the performance of
surveillance methods over longer time spans and in the presence of
different control strategies.
While parameters governing the topology of the contact
network for TB are not known, the network approach adopted
here allows individuals to be more likely to transmit disease to
close social contacts than to random individuals, and allows these
close social contacts to be in contact with each other (clustering);
again, the network is not intended to duplicate the contact
structure of a particular community. For the simulations we
present here, we use networks with 100,000 vertices and moderate
locality parameter (D=5) and mean degree (n=15). Importantly,
the qualitative results we present are not sensitive to these choices,
and in fact hold over a range of parameter choices leading to
growing drug-resistant TB epidemics.
In our model, individuals are counted as incident drug resistant
cases in the simulated surveys if they have resistant disease at the
time they are diagnosed as TB cases; thus, DR TB cases due to
primary transmission of resistance and DR TB cases who have
acquired resistance during a previous course of therapy and
subsequently re-present with resistant disease will be identified.
Conversely, we have assumed that individuals who present with
drug sensitive disease and acquire resistance during the current
course of therapy will not be identified as resistant cases in these
surveys since at the time of diagnosis they would not have been
identified as DR TB cases. As such, in these simulations we have
assumed that cases of acquired resistance will be detected only
among those who re-present with previously treated disease; the
effect of relaxing this assumption is examined in the Discussion.
We first compare the incidence-based survey estimate of the
proportion of incident disease which is resistant to the calculated
proportion resistant among all individuals moving into or between
TB disease states which includes those who acquire drug resistance
during the current course of therapy. We also compare the
incidence-based estimate of resistance to the total burden of
resistant among prevalent tuberculosis cases calculated at the end
of each year.
Results and Discussion
The rising trends of TB incidence, prevalence, and drug
resistance during the simulated epidemics is shown in Figure 3; the
solid and dotted lines depict the mean values for fifty simulated
epidemics executed on five different contact networks (each with
n=15 and D=5). The shaded areas reveal where 95% of the
simulated epidemics fell and reflect variability resulting from both
the differences in the realized topology of the contact networks and
the inherent stochasticity of the tuberculosis epidemics transmitted
on these networks.
We then simulate the performance of incidence-based sampling
and compare the estimated fraction of sampled incident cases which
are DR to the fraction of all incident cases which are DR; in this
latter fraction we include all cases of acquired drug resistance in
both the numerator and the denominator. Figure 4A shows that
incidence-based surveys will underestimate the actual proportion
of incident cases that are resistant during the stages of the epidemic
when acquired resistance is important. Since DR TB first appears
through the acquired route, incidence-based surveys are most
prone to underestimate resistance as it is first emerging in a
population.
As transmission of DR TB becomes an increasingly important
mechanism for the continued emergence of resistance, incidence-
based surveys produce less biased results. Figure 4C shows
substantial reductions in the proportion of incident drug-resistant
cases missed by incidence-based sampling during latter stages of an
emergent DR TB epidemic. For simplicity in these simulations, we
have assumed that the relative transmissibility of the DR strain is
fixed at 80% of the transmissibility of the DS strain. In reality, we
expect that strain competition would result in selection of
increasingly transmissible resistant strains, such that the mean
fitness costs of resistance will decrease as the epidemic progresses.
While there are not adequate data to describe the time at which an
emerging DR TB epidemic switches from being driven by the
acquired-resistance mechanism to being driven by transmitted
resistance, Figure 5 shows how this transition is dependent upon
the distribution of fitness costs associated with resistance. We note
that even if fitness costs are fixed (Fig. 5, solid line), the relative
importance of transmission increases as resistant strains, initially
appearing through inadequate treatment of those with DS TB,
become more prevalent. As with other tuberculosis models with
similar underlying assumptions about the natural history and
parameters, we find that if all DR strains suffer total fitness deficits
greater than 20 to 30% when compared to DS strains, DR TB
does not emerge to become a substantial public health threat.
We also investigate the relationship between the fraction of
sampled incident TB that is DR, and the fraction of prevalent TB in
Figure 3. Simulated epidemics. Means and approximate 95% CIs for
simulated DR TB epidemics reflecting the incidence (red line, orange
shading), prevalence (green line, lime shading), and proportion of
disease which is DR (lower subfigure).
doi:10.1371/journal.pone.0002363.g003
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cases is greater than that for drug-susceptible TB (under the
assumption that those infectious with DR strains will not respond
as well to standard therapy), the fraction of DR among prevalent
disease will be greater than the fraction resistant among incident
disease. This enrichment of resistance among prevalent TB cases is
Figure 4. Estimation of burden of resistance based on samples of incident TB cases. The proportion of resistance among incident cases
included in surveys (y-axis for all subplots) is graphed against the actual proportion of incident disease which is drug-resistant (x-axis for subplots A,
C, E, and G) and against the actual proportion of prevalent disease which is drug-resistant (x-axis for subplots B,D,F, and H). The insets for subplots A–
D show the fraction by which the proportion of TB which is DR is underestimated by the survey (y-axis) plotted by the true proportion which is
resistant (x-axis). Subplots show the relationship between the surveyed and actual proportions of TB that is resistant during early (A,B) and later
periods (C–H) of DR TB epidemics. Three different scenarios are depicted for later periods: no additional interventions to control DR TB (C,D),
interventions which limit acquired drug resistance (E,F), and interventions which improve treatment of drug-resistant disease (G,H).
doi:10.1371/journal.pone.0002363.g004
Figure 5. Dominant mechanisms driving resistance change as the epidemic progresses. The mean of the ratio of transmitted to acquired
resistance is plotted over 50 years of a simulated epidemic. The rate of increase in this ratio depends on how the relative fitness of resistant strains
change over time: four examples are provided, in which the relative fitness of strains remains constant at 80%, increases from 80 to 100% over 50
years, increases from 80 to 100% over 25 years, and increases between 50 and 100% over 50 years, respectively.
doi:10.1371/journal.pone.0002363.g005
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emergence of DR TB; in contrast with the substantial reduction in
bias associated with incidence-based sampling as the epidemic
progresses, the disparity between resistance among samples of
incident and prevalent cases remains relatively stable in these
simulations, since the duration of DR TB infectiousness is not
affected by the mechanism by which the resistance first appeared.
We find that the introduction of interventions against the
emergence of DR TB can alter the relationship between the
fraction of sampled incident cases that is DR and both the fraction
of all incident cases that is DR and the fraction of prevalent cases
that is DR. For example, interventions which reduce acquired
resistance, such as the improvement of patient adherence to long
and complex drug regimens, can reduce the magnitude of bias in
incidence-based estimates of resistance (compare Fig. 4E to Fig.
4C), but may also appear less effective than they really are because
the burden of resistance prior to the initiation of the intervention
will be underestimated. In contrast, efforts directed at improving
the management of DR TB, through the use of drug-sensitivity
testing and access to appropriate second-line and third-line
antibiotics, do not change the bias in incidence-based estimates
of the burden of resistance (compare Fig. 4G to Fig. 4C). As
expected, if we reduce the mean duration of DR TB cases to be
similar to that of DS TB cases, e.g. by instituting control programs
which rapidly detect and appropriately treat DR TB, the fraction
of incident cases which are resistant becomes a better proxy for the
fraction of prevalent cases which are resistant (Fig. 4H).
Our approach, in which we use reduced models of TB
epidemics and simplified simulations of drug-resistance surveys,
is intended to illustrate potential sources of bias associated with
current methods of estimating the burden of drug-resistance from
samples of incident TB cases. We use an individual-based model
that allows us to directly simulate a sampling process; we can then
test for bias by comparing DR TB in our sampled subset to DR
TB in the entire population.
The insight we derive from this exercise is qualitative in nature.
Since there are several important areas of uncertainty, for
example, the manner and degree to which drug-resistance
conferring mutations affects the reproductive capacity of the
mycobacteria, the rates of acquired resistance during therapy, and
the frequency of re-infection and coinfection among others, our
ability to make conclusive statements about the magnitude and
timing of biases associated with drug resistance surveys conducted
among incident TB cases is very limited. Rather than focus on
quantifying the amount of bias and specifying the time at which we
would expect to see these biases change in the presence and
absence of interventions, we have chosen to focus on several key
qualitative insights. First, we find that estimates derived from
samples of incident TB cases may underestimate the total burden
of DR TB. Because individuals acquiring drug resistance while on
therapy are less likely to be included in samples of incident cases,
the fraction of DR TB among sampled incident cases undercounts
resistance among all incident cases. We note that in our results we
have assumed that cases which acquire DR TB during their
current course of therapy will not be included in samples of
incident DR TB; as such, the estimated magnitude of bias
associated with these samples will be reduced in settings in which
all cases of acquired resistance are captured in these surveys.
However, since a portion of these cases of acquired resistance are
likely to be missed, this bias will occur, and will be greatest when
resistance is first emerging in a population. Thus, we suggest that
incidence-based samples may not be adequately sensitive to detect
resistance as it first appears in a community. Since the resources
needed to limit the spread of resistance in its early stages are
substantially less than those needed to address a mature DR TB
epidemic, the fact that we may not detect the emergence of
resistance in its earliest stages is especially disquieting. Others have
argued that estimates of the number of incident cases of DR TB
(rather than just the fraction of incident cases which are resistant) is
also an important statistic to report [34,35].
Second, we also demonstrate that resistance among prevalent
TB cases will be greater than among incident TB cases if the mean
duration of DR TB disease is longer than that of DS TB disease.
While it is possible that in some settings co-occurrence of
resistance and host factors associated with reduced disease
duration (i.e. HIV infection) may actually lead to shorter average
durations of disease for those with DR TB, in most situations the
DR phenotype will result in failure of standard treatments and a
protracted disease course. Since resistance among prevalent cases
determines the current resources needed to address extant DR TB
in the community, and represents the source of ongoing resistance
transmission, estimates of the total burden of DR TB would ideally
reflect resistance among prevalent cases. Because studies designed
to capture incident cases of acquired DR TB and to measure
prevalence of DR TB at the population level may prove too costly
and logistically difficult in most settings, we suggest that current
estimates from incident based samples should be viewed as a lower
bound of the probable burden of resistance.
There are several important factors which are not included in
our simple model and which limit the generalizability of our
arguments. In particular, we have focused on epidemics of TB in
the absence of concurrent HIV co-epidemics. Because HIV
infection fundamentally alters the natural history of TB disease
among co-infected individuals and changes the transmission
dynamics of TB on a population-level, our findings cannot be
directly extended to areas in which HIV plays a major role in the
emergence of TB and drug resistant TB. We have also not
considered the affects of geographic heterogeneity or the role of
the private sector in TB treatment, both of which are factors that
complicate the measurement of the burden of drug resistant TB;
we have discussed the additional challenges posed by these factors
elsewhere [36]. The finding that the fraction of incident cases
which is drug resistant will be underestimated, especially early in
the emergence of drug resistant TB, should hold in situations
where acquired drug resistance is how resistance first emerges and
where cases of acquired drug resistance may be undercounted.
The finding that the fraction of incident cases that is resistant will
be less the fraction of prevalent cases which is resistant will apply
to areas where the average duration of those with drug resistant
disease is longer than for those with drug sensitive disease.
Incident-based drug resistance surveys have a very important
continuing role in the worldwide assessment of the burden of drug-
resistant TB. Because they are relatively easy to implement, they
can provide comparable information across many regions of the
globe. However, it is important to recognize that these incidence
survey approaches do not provide a complete account of the
burden of resistance and may, in many circumstances, underes-
timate the investment in resources that will be required to confront
the total burden of resistance within communities.
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corner shows the natural history model structure; the events
possible from each of the disease states are linked to this overall
model by the letters A through F.
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Figure S2 Four hypothetical patient histories demonstrating the
time-dependent (relative to infection and re-infection events) rates
of progression to active tuberculosis. The height of the bars
represents the probability of disease, and the color of the bars
correspond to the type of infection (green, drug-sensitive; red,
drug-resistant; yellow, mixed). The relative heights of the red and
green bars depend on the respective relative fitness of resistant and
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probability of progression to disease is lower after re-infection than
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